Pure Global
NCT06409338

Research on the Brain Mechanism of taVNS in Regulating PD Motor Symptoms

Research on the Brain Mechanism of Transcutaneous Auricular Vagus Nerve Stimulation in Regulating PD Motor Symptoms
The First Affiliated Hospital with Nanjing Medical University·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Parkinson Disease
Drug/Device/Intervention
Transcutaneous auricular vagus nerve stimulation (active）
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
The First Affiliated Hospital with Nanjing Medical University
Location
Nanjing, China
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Sep 01, 2024
Enrollment
32 participants
Primary outcome

alterations in functional topological properties within the cortex of bilateral cerebral hemispheres-Sigma,alterations in functional topological properties within the cortex of bilateral cerebral hemispheres-global efficiency (Eg),alterations in functional topological properties within the cortex of bilateral cerebral hemispheres-local efficiency (Eloc),alterations in functional topological properties within the cortex of bilateral cerebral hemispheres-nodal efficiency (Ne),changes in MEPs values,changes in RMT values,changes in CSP values,changes in SICI values,changes in ICF values

Summary

This study is a double blind comparative study exploring the neural underpinnings of taVNS
 modulating PD motor deficits. We hypothesize that taVNS might improve PD motor deficits by
 regulating the balance between excitation and inhibition in the primary motor cortex.

ICD-10 classifications
Parkinson diseaseParkinsonism in diseases classified elsewhereDementia in Parkinson diseaseSecondary parkinsonismSecondary parkinsonism, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409338
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06409338 through Pure Global AI's free database. This phase not specified trial is sponsored by The First Affiliated Hospital with Nanjing Medical University and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.